Last 23.50 GBp
Change Today -0.50 / -2.08%
Volume 37.0K
VENN On Other Exchanges
Symbol
Exchange
London
As of 11:36 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

venn life sciences holdings (VENN) Snapshot

Open
24.00 GBp
Previous Close
24.00 GBp
Day High
24.25 GBp
Day Low
23.50 GBp
52 Week High
01/26/15 - 26.25 GBp
52 Week Low
12/22/14 - 15.50 GBp
Market Cap
6.7M
Average Volume 10 Days
15.0K
EPS TTM
-0.09 GBp
Shares Outstanding
28.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VENN LIFE SCIENCES HOLDINGS (VENN)

Related News

No related news articles were found.

venn life sciences holdings (VENN) Related Businessweek News

No Related Businessweek News Found

venn life sciences holdings (VENN) Details

Venn Life Sciences Holdings plc, a clinical research organization, provides clinical trial management and resourcing solutions to pharmaceutical, biotechnology, and medical device clients in France, Germany, the Netherlands, the United Kingdom, Ireland, and Europe. It offers a range of clinical trial services, including protocol development, feasibility, investigator qualification and site selection, project management, medical monitoring, clinical monitoring of Phases I – IV, site management, patient recruitment, data management, biostatistics/data analysis, medical writing, pharmacovigilance regulatory services, organisation of investigator meetings, quality assurance, electronic data capture, IVRS/IWRS, and methodology consulting. The company was incorporated in 2011 and is based in London, the United Kingdom.

39 Employees
Last Reported Date: 05/16/14

venn life sciences holdings (VENN) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €152.0K
Compensation as of Fiscal Year 2013.

venn life sciences holdings (VENN) Key Developments

Venn Life Sciences Holding Plc Appoints Gracielle Anna Maria Beijerbacht-Schutjens to the Board as an Executive Director

Venn Life Sciences Holding Plc announced the appointment of Gracielle Anna Maria Beijerbacht-Schutjens to the Board as an Executive Director with immediate effect. Gracielle worked with a pharmaceutical, biotechnology and medical device companies, Gracielle has managed clinical trials across multiple sites with extensive investigator relationships throughout the Benelux region and is a member of a number of professional research associations.

Venn Life Sciences Holding Plc Provides Earnings Guidance for the Year 2015

Venn Life Sciences Holding Plc provided earnings guidance for the year 2015. For the period, the company announced a strong close to 2014 with November seeing a record billing month in excess €900,000 and full year revenues are expected to be at least double the previous year's revenues. This strong close has been driven by substantial contract wins since May this year exceeding €8 million in total value and provides a firm foundation for 2015. The Company already has contracted revenue for next year in excess of €6 million, as well outstanding proposals for new contracts worth a total of €18 million. With significant secured revenue for 2015 and the expectation that the Company will secure further contracts that will contribute to 2015, the Company is confident that it will deliver profitability and significant revenue growth next year.

Venn Life Sciences Announces the Signing of an Agreement Worth €1.4 Million

Venn Life Sciences announced the signing of an agreement worth over €1.4 million to conduct a European wide Phase II study for a US based company. The deal comes on the back of multiple significant contract signings for Venn this year and sees the Company expanding its US customer base. Including this contract, Venn has announced new business wins totaling €8 million in the past six months. This volume of business represents a major step change for Venn and justifies the significant investment in personnel and infrastructure in the past 18 months.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VENN:LN 23.50 GBp -0.50

VENN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VENN.
View Industry Companies
 

Industry Analysis

VENN

Industry Average

Valuation VENN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.7x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENN LIFE SCIENCES HOLDINGS, please visit www.vennlifesciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.